Skip to main content
Clinical Trials/NCT04451148
NCT04451148
Unknown
Not Applicable

Gut Microbiome As Target of Intervention Against Obesity and Metabolic Syndrome

Federico II University1 site in 1 country120 target enrollmentMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity, Childhood
Sponsor
Federico II University
Enrollment
120
Locations
1
Primary Endpoint
Concentration of metagenomic characteristics of the intestinal microbiota in subjects with obesity, obesity complicated by metabolic syndrome and healthy controls
Last Updated
5 years ago

Overview

Brief Summary

Pediatric obesity is a risk factor for the onset of obesity in adulthood and is a risk factor for various chronic non-communicable diseases. Metabolic syndrome (MS) is the name for a group of risk factors that increase cardiovascular risk and other health problems characterized by the presence of abdominal obesity, dyslipidemia, hyperglycaemia and high blood pressure. Numerous preclinical and clinical data suggest a potential role of the intestinal microbiota in these diseaes. Unfortunately, comparative studies of the gut microbiota are still scarce in pediatric subjects suffering from obesity than obesity complicated by MS. The aim is to study the metagenomics and metabolomics characteristics of the intestinal microbiota in obese children/adolescents with or without MS, that could provide useful data for innovative intervention strategies for these conditions.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
May 1, 2022
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Federico II University
Responsible Party
Principal Investigator
Principal Investigator

Roberto Berni Canani

MD, Associate Professor

Federico II University

Eligibility Criteria

Inclusion Criteria

  • Subjects aged between 10-16 years,
  • diagnosis of obesity or obesity complicated by metabolic syndrome
  • healthy controls

Exclusion Criteria

  • Age at enrollment \< 10 or \>16 years,
  • concomitant presence of chronic diseases,
  • neoplasms,
  • immunodeficiencies,
  • chronic infections,
  • autoimmune diseases,
  • chronic inflammatory bowel diseases,
  • celiac disease, -genetic-metabolic diseases, -
  • cystic fibrosis
  • chronic lung diseases,

Outcomes

Primary Outcomes

Concentration of metagenomic characteristics of the intestinal microbiota in subjects with obesity, obesity complicated by metabolic syndrome and healthy controls

Time Frame: at enrollment

Evaluation of gut microbiota composition

Secondary Outcomes

  • Concentration of the metabolomic characteristics of the intestinal microbiota in subjects with obesity, obesity complicated by metabolic syndrome and healthy controls(at enrollment)
  • Concentration of metabolomic characteristics of the intestinal microbiota in subjects with obesity, obesity complicated by metabolic syndrome and healthy controls(at enrollment)

Study Sites (1)

Loading locations...

Similar Trials